Study of 18F-Florastamin PET/CT Imaging in Patients With at Least Intermediate Risk Prostate Cancer
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
In this study, 18F-Florastamin PET/CT will be performed in patients with at least
intermediate risk prostate cancer, to assess the diagnostic performance and safety of
18F-Florastamin PET/CT imaging.
This study will first carry out the pilot study (including pharmacokinetics and radiation
dosimetry).